Serum Endocan Levels in Colorectal Cancer

This case-control study aims to measure serum endocan levels in patients with colorectal cancer and healthy controls using ELISA and to compare the levels between the two groups.

Not yet recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Colorectal Cancer Colonic Diseases Colorectal Neoplasms Digestive System Diseases Digestive System Neoplasms Gastrointestinal Diseases Gastrointestinal Neoplasms Intestinal Diseases Intestinal Neoplasms Neoplasms Neoplasms by Site Rectal Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

About this study

Colorectal cancer is a major cause of cancer-related morbidity and mortality. Circulating biomarkers such as endocan may provide useful information about disease characteristics.

This observational study will include newly diagnosed colorectal cancer patients and age- and sex-matched healthy controls. Serum endocan levels will be measured by enzyme-linked immunosorbent assay (ELISA) before any treatment.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

- Age 18 years or older
Newly diagnosed colorectal cancer confirmed by histopathology (cases)
No previous surgery, chemotherapy, or radiotherapy for colorectal cancer
Healthy adults with no history of cancer or inflammatory bowel disease (controls)
Written informed consent

Exclusion criteria

- Previous malignancy
Previous chemotherapy or radiotherapy for colorectal cancer
Active infection
Autoimmune disease
Chronic liver disease
Chronic kidney disease
Pregnancy

Treatment and study plan

Primary outcomes

Mean serum endocan level

Time frame: Baseline

Mean serum endocan concentration (ng/mL) measured by ELISA in colorectal cancer patients compared with healthy controls.

Secondary outcomes

Serum endocan level according to tumor stage

Time frame: Baseline

Mean serum endocan concentration according to TNM tumor stage.
Serum endocan level according to histological grade

Time frame: Baseline

Mean serum endocan concentration according to histological grade.
Serum endocan level according to lymph node status

Time frame: Baseline

Mean serum endocan concentration in patients with and without lymph node involvement.
Serum endocan level according to distant metastasis

Time frame: Baseline

Mean serum endocan concentration in patients with and without distant metastasis.

Interested in participating?

Not yet recruiting

Trial opening soon.

Get Notified

Sponsors and collaborators

Lead sponsor

Assiut University

Other

Registry information

Official study title

Serum Endocan Levels Measured by ELISA in Colorectal Cancer: Relation to Clinicopathological Features

Important dates

Study start: 2026
Primary completion: 2027
Study completion: 2028
First posted: Sep 25, 2026
Registry last updated: Sep 25, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not yet recruiting